Full Press Release Details
Life Science Biosensor Diagnostics Pty Ltd Statement
in Relation to Recent Sale of Shares in GBS Inc
Life Science Biosensor Diagnostics Pty Ltd (LSBD)
is the owner and licensor of the Biosensor platform currently licensed to GBS Inc and other corporations globally. The objective of LSBD
is to develop its biosensor diagnostic test portfolio to be commercialized by its licensees in real time at the point of care, either
by health care professionals or by the patients directly. This means making diagnostic testing accessible to the people that need it
As LSBD continues the development and commercialization
of the biosensor diagnostic test portfolio, an ongoing capital intense Research and Development (R&D) and commercialization plan
expected for the next 5 years, which will require funding by LSBD and its subsidiary companies, it continues to support the management
of its licensee GBS Inc and the saliva based glucose and COVID tests.
LSBD forecasts to generate this investment in R&D
funding from licensing revenue, sales royalties, and, if required, as in this case, divestment of shares LSBD owns in investee companies
it lists on the capital markets.
After the current saliva based glucose and COVID
tests, the next phase planned for this biosensor diagnostic test portfolio will include subsequent research and development of approximately
150 different real time point of care diagnostic tests, in the diagnostic segments of clinical biochemistry, immunology, endocrinology,
allergology, oncology and genomics.
George Syrmalis - Director
Life Science Biosensor Diagnostics Pty Ltd